The estimated Net Worth of Michael Andrew Chambers is at least $36.5 Milion dollars as of 16 August 2024. Michael Chambers owns over 37,038 units of Sarepta Therapeutics Inc stock worth over $36,467,125 and over the last 2 years Michael sold SRPT stock worth over $0.
Michael has made over 6 trades of the Sarepta Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Michael bought 37,038 units of SRPT stock worth $4,955,684 on 16 August 2024.
The largest trade Michael's ever made was buying 57,100 units of Sarepta Therapeutics Inc stock on 14 September 2022 worth over $5,962,953. On average, Michael trades about 20,884 units every 73 days since 2022. As of 16 August 2024 Michael still owns at least 284,034 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Michael Chambers stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142.
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry oraz M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: